NYSE · Health care

Nanoviricides, Inc. (NNVC)

Nanoviricides, Inc. reported revenue of $0 in fiscal 2026. It posted a net loss of $8.2M. In fiscal 2026 capital spending exceeded operating cash flow by $7.8M. At June 30, 2026 it held $2.8M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 28, 2026.

Watch NNVC in 60 seconds

Price

$1.38

-2.82% on the day · November 11, 2026

52-week range $0.85 to $1.93

Market cap

$35.1M

Revenue (FY2026)

Key facts about Nanoviricides, Inc.

Net worth: Nanoviricides, Inc. has a market value (market cap) of $35.1M at the latest share price, and shareholders' equity of $8.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2026 revenue was $0, with a net loss of $8.2M.
Cash flow: In fiscal 2026 operations used $7.7M of cash.
Latest report: The latest periodic report (annual report, 10-K) was filed with the SEC on September 28, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: Nanoviricides, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Nanoviricides, Inc. does

Nanoviricides, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker NNVC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	$0	-$8.3M	-$8.2M	-$0.41	-$7.8M
2025	$0	-$9.6M	-$9.5M	-$0.63	-$8.5M
2024	$0	-$8.5M	-$8.3M	-$0.70	-$6.5M
2023	$0	-$8.9M	-$8.6M	-$0.74	-$5.8M
2022	n/a	-$8.1M	-$8.1M	-$0.70	-$6.2M
2021	n/a	-$8.7M	-$8.8M	-$0.81	-$8.5M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Latest SEC filings

What Nanoviricides, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 29, 2026
Executive or director change8-KNanoViricides extended the employment agreements for its President and Chief Financial Officer through June 30, 2027.
September 28, 2026
Annual report10-K · period to June 30, 2026NanoViricides reported a reduced net loss for fiscal year 2026 but raised substantial doubt about its ability to continue as a going concern.Diluted EPS -$0.41 versus -$0.63.
August 21, 2026
Shelf registration to sell securities S-3
July 30, 2026
Material agreement 8-K
July 17, 2026
Material agreement 8-K
June 22, 2026
Form DEL AM filing DEL AM
June 17, 2026
Form DEL AM filing DEL AM
June 15, 2026
Shelf registration to sell securities S-3
June 5, 2026
Shelf registration to sell securities S-3
May 21, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 3, the latest on January 28, 2025. Insider transactions on SEC

Insider trades

What the people running Nanoviricides, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about NNVC

What does Nanoviricides, Inc. do?

Nanoviricides, Inc. is a company in the Health care sector, listed on NYSE as NNVC. Its shares trade on NYSE under the ticker NNVC.

What is Nanoviricides, Inc.'s net worth?

Nanoviricides, Inc. has a market value (market cap) of $35.1M at the latest share price, and shareholders' equity of $8.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Nanoviricides, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $8.2M.

How much revenue does Nanoviricides, Inc. make?

In fiscal 2026 Nanoviricides, Inc. reported revenue of $0.

When did Nanoviricides, Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on September 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 29, 2026.

When is Nanoviricides, Inc.'s next earnings report?

Nanoviricides, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Mira Pharmaceuticals, Inc.

ATNM

Actinium Pharmaceuticals, Inc.

RADX

Radiopharm Theranostics Ltd

CRVO

CervoMed Inc.

Compare NNVC with

Compare NNVC with any company

Follow NNVC

Get an email when Nanoviricides, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Nanoviricides, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.